We make tomorrow’s treatments available to patients today through innovative clinical trials found only here.
2023 Clinical Trials Facts
9,606
patients in clinical trials
1,568
clinical trials
MD Anderson has the nation's largest cancer clinical trials program, and our Cancer Network® partners across the country allow us to enroll a different and diverse patient population into trials: key to achieving our mission of Making Cancer History®.
Featured Clinical Trial Articles
News
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
AACR: Trio of studies highlights promising early results with new cancer therapies and targets
AACR: Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancer
Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients
Biomarker-directed combination effective in immunotherapy-resistant lung cancer
Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies
Patient Stories
Immunotherapy
Immunotherapy approaches unleash our immune systems against cancer. MD Anderson has more than 160 clinical trials testing drugs and cellular therapies that stimulate and support immune attack against many different types of cancer. The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Our human research protection program has rigorous quality standards and has been granted full accreditation by the Association for the Accreditation of Human Research Protection Programs, Inc.